HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT

Formulations of the HIV compounds atazanavir and cobicistat such as tablet comprising atazanavir and cobicistat comprising having less than about 3% total cobicistat impurities after 8 weeks at 40 ° C and 75% relative humidity.

Saved in:
Bibliographic Details
Main Authors Koo, Otilia May Yue, Kottala, Niranjan Kumar, Nikfar, Faranak, Tao, Jing, Varia, Sailesh A
Format Patent
LanguageCroatian
English
Published 25.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Formulations of the HIV compounds atazanavir and cobicistat such as tablet comprising atazanavir and cobicistat comprising having less than about 3% total cobicistat impurities after 8 weeks at 40 ° C and 75% relative humidity.
AbstractList Formulations of the HIV compounds atazanavir and cobicistat such as tablet comprising atazanavir and cobicistat comprising having less than about 3% total cobicistat impurities after 8 weeks at 40 ° C and 75% relative humidity.
Author Koo, Otilia May Yue
Nikfar, Faranak
Varia, Sailesh A
Kottala, Niranjan Kumar
Tao, Jing
Author_xml – fullname: Koo, Otilia May Yue
– fullname: Kottala, Niranjan Kumar
– fullname: Nikfar, Faranak
– fullname: Tao, Jing
– fullname: Varia, Sailesh A
BookMark eNrjYmDJy89L5WQw8_AMUwgJcnUM8XX1C1Fw8w_yDfVxDPH091Pwd1NwDHGMcvRzDPMMUnD0c1Fw9nfydPYMDnEM4WFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8R5BAUYGRkaGhkZmISGGxsSpAgDX5ysq
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate FORMULACIJA ATAZANAVIRA I KOBICISTATA ZA LIJEČENJE HIV-A
ExternalDocumentID HRP20221126TT1
GroupedDBID EVB
ID FETCH-epo_espacenet_HRP20221126TT13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:18:27 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Croatian
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_HRP20221126TT13
Notes Application Number: HR2022P001126T
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221125&DB=EPODOC&CC=HR&NR=P20221126T1
ParticipantIDs epo_espacenet_HRP20221126TT1
PublicationCentury 2000
PublicationDate 20221125
PublicationDateYYYYMMDD 2022-11-25
PublicationDate_xml – month: 11
  year: 2022
  text: 20221125
  day: 25
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Bristol-Myers Squibb Holdings Ireland Unlimited Company
RelatedCompanies_xml – name: Bristol-Myers Squibb Holdings Ireland Unlimited Company
Score 3.4367404
Snippet Formulations of the HIV compounds atazanavir and cobicistat such as tablet comprising atazanavir and cobicistat comprising having less than about 3% total...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221125&DB=EPODOC&locale=&CC=HR&NR=P20221126T1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIDSt-I-ks49FMnSllbsBzUbw5exdi2KsI2t4r_vpXbOp70lOTgugct9JL87gHu0ADl6CqnenaZMpzRj-mM3Uf1N8lmSsnb-i-P2A8Md0ucxG9fgc4OFKeuEfpfFEVGjUtT3oryvl9skllX-rVw_JB-4tHhypGlpVXTcwXCmwzRrYNpRaIVCE8J0Yy2IzagiGhJDpT30o3tKHezRQMFSlv9tinMM-xGymxcnUHtfNeBQbFqvNeDAr168cVgp3_oUDNcbERnbXKoC_ATDN3_4UqaYSOgQLvkbD_jIiwkPLCLCgSe8V8nlGdw5thSujgJM_rY7ceOtsLLdPYf6fDHPLoD0GDNUPa20nfUpo0aSpHmftSid9fOeMW1dQnMXp6vd5Gs4UjOFs-uwJtSL1Vd2gwa3SG7Lg_oB4_B-iA
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwED7GFOebTsUfUwNK34rbmnT2oUiWtrS6tqNmY_gy1q5FEbqxVfz3TWrnfNpbyMFxCVzuvkvuC8C9iACZyBQSVZslRMU4JeqjFsv_TbJ5nJBO9tvH7Qe6O8LPEzKpweemF6bkCf0uyRGFRyXC34vyvF5ui1hW-bZy_RB_iKnFk8NNS6nQcVfAmS5RrL5pD0MrZApjphspQWQOK6HOBVTaEzl2T7qDPe7LtpTl_5jiHMH-UKjLi2Oova-a0GCbr9eacOBXN95iWDnf-gR01xsjHtmUSwJ-JOCbPxqUJSYUOohy-kYDOvYiRAMLsbDvMe-VU34Kd47NmasKA6Z_y5260dZY3tHOoJ4v8vQcUI8QXfJpJZ3UwATrcZxkBmljPDeynj5rX0Brl6bL3eJbaLjcH0wHXvByBYdSInvuuqQF9WL1lV6L4FvEN-Wm_QD-tYF7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=HIV+TREATMENT+FORMULATION+OF+ATAZANAVIR+AND+COBICISTAT&rft.inventor=Koo%2C+Otilia+May+Yue&rft.inventor=Kottala%2C+Niranjan+Kumar&rft.inventor=Nikfar%2C+Faranak&rft.inventor=Tao%2C+Jing&rft.inventor=Varia%2C+Sailesh+A&rft.date=2022-11-25&rft.externalDBID=T1&rft.externalDocID=HRP20221126TT1